Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis

There is no established postoperative adjuvant therapy for hepatocellular carcinoma (HCC), and improvement of patient prognosis has been limited. We conducted long‐term monitoring of patients within a phase II trial that targeted a cancer antigen, glypican‐3 (GPC3), specifically expressed in HCC. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Masatake, Mizuno, Shoichi, Yoshikawa, Toshiaki, Fujinami, Norihiro, Sugimoto, Motokazu, Kobayashi, Shin, Takahashi, Shinichiro, Konishi, Masaru, Gotohda, Naoto, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419030/
https://www.ncbi.nlm.nih.gov/pubmed/32449239
http://dx.doi.org/10.1111/cas.14497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419030/
https://www.ncbi.nlm.nih.gov/pubmed/32449239
http://dx.doi.org/10.1111/cas.14497

Ejemplares similares